ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. John Byrd on Bruton's Tyrosine Kinase in CLL

John C. Byrd, MD
Published: Tuesday, Jan 29, 2013

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's Tyrosine Kinase (BTK) in chronic lymphocytic leukemia (CLL).

Byrd says that BTK is expressed mostly in B-cells but also in some normal blood cells. BTK is crucial to the survival and proliferation of CLL as well as other B-cell blood cancers. Ibrutinib is an oral agent that inhibits BTK irreversibly and can be taken once daily to see contented effect.

A study was presented at the 2012 American Society of Hematology Annual Meeting and Exposition looking at ibrutinib in patients with naïve and relapsed or refractory CLL or small lymphocytic lymphoma. The results of the study showed that patients responded well to ibrutinib. Additionally, treatment was well tolerated in all CLL groups, including high-risk and older treatment-naïve patients.

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's Tyrosine Kinase (BTK) in chronic lymphocytic leukemia (CLL).

Byrd says that BTK is expressed mostly in B-cells but also in some normal blood cells. BTK is crucial to the survival and proliferation of CLL as well as other B-cell blood cancers. Ibrutinib is an oral agent that inhibits BTK irreversibly and can be taken once daily to see contented effect.

A study was presented at the 2012 American Society of Hematology Annual Meeting and Exposition looking at ibrutinib in patients with naïve and relapsed or refractory CLL or small lymphocytic lymphoma. The results of the study showed that patients responded well to ibrutinib. Additionally, treatment was well tolerated in all CLL groups, including high-risk and older treatment-naïve patients.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x